XML 13 R2.htm IDEA: XBRL DOCUMENT v3.25.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Mar. 31, 2025
Sep. 30, 2024
Current assets:    
Cash and cash equivalents $ 6,823,260 $ 6,431,095
Accounts receivable, net of allowance for credit losses of $82,723 and $75,000 at March 31, 2025 and September 30, 2024, respectively 689,887 362,013
Inventories 348,866 438,592
Prepaid expenses and other current assets 568,398 815,970
Total current assets 8,430,411 8,047,670
Property and equipment, net 683,887 553,233
Other assets:    
Restricted cash 750,000 750,000
Intangible assets 2,698,975 2,698,975
Operating right of use asset 472,390 739,162
Total assets 13,035,663 12,789,040
Current liabilities:    
Accounts payable and accrued liabilities 1,409,628 1,793,427
Operating lease liability, current 472,390 545,912
Deferred revenue 12,285 58,785
Total current liabilities 1,894,303 2,398,124
Long term accrued liabilities 31,467 31,467
Deferred revenue, long term 194,000 194,000
Operating lease liability, long term   193,249
Deferred tax liability, net 684,115 684,115
Warrants classified as a liability 7,570 320,000
Total liabilities 2,811,455 3,820,955
Commitments and contingencies (Note G)
Applied DNA Sciences, Inc. stockholders' equity:    
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of March 31, 2025 and September 30, 2024
Common stock, par value $0.001 per share; 200,000,000 shares authorized as of March 31, 2025 and September 30, 2024; 6,331,410 and 206,324 shares issued and outstanding as of March 31, 2025 and September 30, 2024, respectively 6,331 206
Additional paid in capital 364,896,649 318,815,166
Accumulated deficit (354,442,994) (309,672,755)
Applied DNA Sciences, Inc. stockholders' equity 10,459,986 9,142,617
Noncontrolling interest (235,778) (174,532)
Total equity 10,224,208 8,968,085
Total liabilities and equity 13,035,663 12,789,040
Series A Preferred stock    
Applied DNA Sciences, Inc. stockholders' equity:    
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of March 31, 2025 and September 30, 2024
Series B Preferred stock    
Applied DNA Sciences, Inc. stockholders' equity:    
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of March 31, 2025 and September 30, 2024